CMSC

Health records show prevalence may be three times the norm in some areas

Post hoc analysis of trial data shows inverse relationship

DISCOMS trial looks at whether MS patients should stop treatment as they age

Posts offer insight into risks, experiences during pregnancy

But monoclonal antibodies offer hope for high-risk people, registry data show

Clinical trial, observational data may not be enough to decide best strategy

Most COVID cases were mild or moderate in patients treated with ofatumumab

Most don't ask for medical guidance, survey shows

Stopping treatment may put MS patients at unnecessary risk

But findings do help estimate needed sample size for a future prospective study

Rapid and robust reduction in activity

But pilot study of laughter therapy saw substantial dropout rate

Unclear benefits with disease-modifying therapies in older patients, asymptomatic patients

Nearly two decades of data showed good outcomes